AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis
Condition: Ulcerative Colitis Interventions: Procedure: Appendectomy; Drug: Infliximab Sponsors: Federico II University; Crohn's and Colitis Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 5, 2023 Category: Research Source Type: clinical trials
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
Condition: Crohn's Disease Intervention: Sponsor: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 5, 2023 Category: Research Source Type: clinical trials
AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis
Condition: Ulcerative Colitis Interventions: Procedure: Appendectomy; Drug: Infliximab Sponsors: Federico II University; Crohn's and Colitis Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 5, 2023 Category: Research Source Type: clinical trials
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
Condition: Crohn's Disease Intervention: Sponsor: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 5, 2023 Category: Research Source Type: clinical trials
AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis
Condition: Ulcerative Colitis Interventions: Procedure: Appendectomy; Drug: Infliximab Sponsors: Federico II University; Crohn's and Colitis Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 5, 2023 Category: Research Source Type: clinical trials
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
Condition: Crohn's Disease Intervention: Sponsor: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 5, 2023 Category: Research Source Type: clinical trials
AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis
Condition: Ulcerative Colitis Interventions: Procedure: Appendectomy; Drug: Infliximab Sponsors: Federico II University; Crohn's and Colitis Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 5, 2023 Category: Research Source Type: clinical trials
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
Condition: Crohn's Disease Intervention: Sponsor: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 5, 2023 Category: Research Source Type: clinical trials
AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis
Condition: Ulcerative Colitis Interventions: Procedure: Appendectomy; Drug: Infliximab Sponsors: Federico II University; Crohn's and Colitis Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 5, 2023 Category: Research Source Type: clinical trials
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
Condition: Crohn's Disease Intervention: Sponsor: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 5, 2023 Category: Research Source Type: clinical trials
AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis
Condition: Ulcerative Colitis Interventions: Procedure: Appendectomy; Drug: Infliximab Sponsors: Federico II University; Crohn's and Colitis Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 4, 2023 Category: Research Source Type: clinical trials
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
Condition: Crohn's Disease Intervention: Sponsor: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 4, 2023 Category: Research Source Type: clinical trials
AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis
Condition: Ulcerative Colitis Interventions: Procedure: Appendectomy; Drug: Infliximab Sponsors: Federico II University; Crohn's and Colitis Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 4, 2023 Category: Research Source Type: clinical trials
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
Condition: Crohn's Disease Intervention: Sponsor: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 4, 2023 Category: Research Source Type: clinical trials
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
Condition: Crohn Disease Interventions: Biological: TNFa Antagonist - Infliximab; Biological: TNFa Antagonist - Adalimumab; Biological: Anti-IL12/23 or anti-IL23 - Ustekinumab; Biological: Anti-IL12/23 or anti-IL23 - Risankizumab; Biological: Anti-integrin - Vedolizumab IV; Biological: Anti-integrin - Ved olizumab IV and SC Sponsors: University of Calgary; Alimentiv Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 3, 2023 Category: Research Source Type: clinical trials
